Professional Documents
Culture Documents
DOI 10.1007/s10847-006-9223-x
O R I G I N A L A RT I C L E
Received: 15 May 2006 / Accepted: 20 October 2006 / Published online: 30 January 2007
Springer Science+Business Media B.V. 2007
C. Schoch
Novartis Pharma AG, WKL-122.4.25, 4057 Basel
Switzerland
e-mail: christian.schoch@novartis.com
J.-C. Bizec
Novartis Pharma AG, WKL-135.4.22, 4057 Basel
Switzerland
e-mail: jean-claude.bizec@novartis.com
G. Kis (&)
Novartis Pharma AG, WSJ-340.50B, 4002 Basel
Switzerland
e-mail: georg.kis@novartis.com
123
392 J Incl Phenom Macrocycl Chem (2007) 57:391–394
100
Voltaren registered formulation with 2% HP- γ-CD
Diclofenac/Cremophor Diclofenac/CFR/CDs
Voltaren old marketed formulation with 5% Cremophor EL
80 Diclofenac with 2% cyclofructan CFR6
Diclofenac sodium 0.1 g Diclofenac sodium 0.1 g Diclofenac with 2% octakis- γ-cd
Amount permeated [µg]
Time [min]
of actives was tested in a modified Franz cell consisting as the tears (‘‘GBR tears’’) or as the aqueous humor
of one donor compartment separated from two (‘‘GBR aqueous humor’’) was added to the epithelial
acceptor compartments by excised pig corneas (see and endothelial compartments, respectively. The solu-
picture below). Preheated Glutathione Bicarbonate tions were gassed with a mixture of 95% air–5% CO2
Ringer solution (GBR) with the same salt composition (about 1–2 bubbles per second) to maintain a pH of
123
J Incl Phenom Macrocycl Chem (2007) 57:391–394 393
80
Cox Cox Cox189 with 2% Cremophor EL
189/Cremophor 189/CFR/CDs
Cox189 with 1% HQA-α-CD
Cox189 with 2% Cyclofructan CFR6
Cox 189 0.1 g Cox 189 0.1 g 60 Cox189 with 2% HP- γ-CD
Time [min]
12
Zaditen Ketotifen/CFR/CD
Ketotifen with 2% hexakis(3,6-anhydro)-α-CD
10
Zaditen eye drops
0.035 0.035 Ketotifen with 2% cyclofructan CFR6
Amount permeated [µg]
7.4. After 30 min of equilibration, the GBR solution on presence of cyclodextrin derivatives. In the case of
the epithelial side was substituted for an air/CO2 sat- diclofenac (Fig. 1) the permeated amount of active is
urated GBR solution containing the drug. Samples of almost 20 times higher in presence of 2% octakis(3,6-
300 (l were taken every hour during a period of 3 h anhydro)-c-CD than in the formulation without per-
from the endothelial side for further HPLC analysis. meation enhancer (Diclofenac/Cremophor EL). In the
Each aliquot was replaced immediately with an equal case of Cox189 the most powerful permeation enhancer
volume of fresh GBR. The concentration of active in tested so far was HQA-a-CD, which was not signifi-
the aliquots was determined by HPLC. cantly different from cyclofructan CFR6. It resulted in
about 5–6 times more Cox189 crossing the cornea than
Results and discussion in absence of permeation enhancer (Fig. 2). The results
with ketotifen fumarate (Fig. 3) showed the same ten-
All the three tested molecules, diclofenac (as sodium), dency. However, the permeation enhancing factor of
Cox189 and ketotifen (as fumarate), exhibited an en- the best molecule, hexakis(3,6-anhydro)-a-CD, was
hanced permeability through excised pig corneas in relatively small and statistically not significant.
123
394 J Incl Phenom Macrocycl Chem (2007) 57:391–394
123